Kenvue (KVUE) Projected to Post Earnings on Thursday

Kenvue (NYSE:KVUE) is expected to announce its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Kenvue to announce earnings of $0.3188 per share and revenue of $3.9660 billion for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 9:30 AM ET.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, May 7th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The company had revenue of $3.91 billion during the quarter, compared to the consensus estimate of $3.84 billion. During the same quarter in the prior year, the company earned $0.24 earnings per share. The firm’s revenue for the quarter was up 4.5% on a year-over-year basis. On average, analysts expect Kenvue to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Kenvue Stock Performance

Shares of KVUE stock opened at $18.98 on Tuesday. The firm has a market capitalization of $36.45 billion, a price-to-earnings ratio of 22.34, a PEG ratio of 1.46 and a beta of 0.47. The stock has a fifty day moving average of $18.62 and a 200 day moving average of $18.03. Kenvue has a 52 week low of $14.02 and a 52 week high of $22.28. The company has a quick ratio of 0.70, a current ratio of 0.98 and a debt-to-equity ratio of 0.67.

Kenvue Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 26th. Shareholders of record on Wednesday, August 12th will be issued a $0.21 dividend. This is a boost from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date is Wednesday, August 12th. This represents a $0.84 annualized dividend and a yield of 4.4%. Kenvue’s dividend payout ratio (DPR) is currently 97.65%.

Insider Buying and Selling at Kenvue

In related news, General Counsel Matthew Orlando sold 38,491 shares of the company’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 1.59% of the stock is owned by insiders.

Institutional Investors Weigh In On Kenvue

A number of institutional investors have recently modified their holdings of KVUE. DV Equities LLC purchased a new position in shares of Kenvue in the 4th quarter worth about $46,000. Quarry LP bought a new stake in Kenvue during the 4th quarter valued at about $76,000. Arax Advisory Partners increased its stake in Kenvue by 219.7% during the 4th quarter. Arax Advisory Partners now owns 4,463 shares of the company’s stock valued at $77,000 after purchasing an additional 3,067 shares in the last quarter. Johnson Financial Group Inc. raised its holdings in Kenvue by 277.8% in the third quarter. Johnson Financial Group Inc. now owns 5,062 shares of the company’s stock worth $82,000 after buying an additional 3,722 shares during the last quarter. Finally, Triumph Capital Management purchased a new position in Kenvue in the third quarter worth about $104,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Zacks Research cut shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Barclays increased their price target on shares of Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 21st. Wall Street Zen upgraded shares of Kenvue to a “buy” rating in a report on Sunday, July 12th. UBS Group lifted their price objective on Kenvue from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Thursday, July 16th. Finally, Citigroup cut their price objective on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 15th. Three analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $19.58.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.